摘要
Abstract
OBJECTIVE: To evaluate the curative effect and cost of sequential therapy with azithromycin for Lower respiratory tract infection. METHODS: A total of 180 patients with lower respiratory tract infection were randomly divided into intravenous therapy group(59 cases), sequential therapy group(62 cases),and p.o. Group(59 cases). The therapeutic effects and the adverse drug reactions of the 3 groups were observed, and the data was subjected to cost-effective analysis in pharmacoeconomics. RESULTS: In intravenous therapy group, sequential therapy group, and p.o. Group, the costs were 296.10, 223.30 and 168.70 yuan, respectively. The clinical effective rates were 91.53% , 90.32% , and 67.80% , respectively. The total bacterial eradication rates were 88.24% , 87.04% , and 66.04%, respectively. The rates of adverse drug reactions were 5%, 5%, and 0, respectively. The cost-effectiveness were 323.50, 247.23, and 248.82, respectively, and the incremental cost-effective ratios in the intravenous therapy group and sequential therapy group were 536.87 and 242.45, respectively as against p.o. Group. CONCLUSION: Among the 3 schemes, sequential therapy with azithromycin with high efficiency and economy is the optimal one, which can reduce bacterial resistance.关键词
阿奇霉素/下呼吸道感染/序贯疗法/成本-效果分析Key words
Azithromycin/ Lower respiratory tract infection/ Sequential therapy/ Cost-effectiveness analysis分类
医药卫生
